Edition:
India

Kazia Therapeutics Ltd (KZIA.OQ)

KZIA.OQ on NASDAQ Stock Exchange Capital Market

5.31USD
19 Apr 2018
Change (% chg)

$-0.25 (-4.58%)
Prev Close
$5.57
Open
$5.51
Day's High
$5.51
Day's Low
$5.31
Volume
1,216
Avg. Vol
5,548
52-wk High
$6.64
52-wk Low
$2.28

Latest Key Developments (Source: Significant Developments)

Kazia Therapeutics And Noxopharm Announce Collaboration
Wednesday, 27 Dec 2017 

Dec 27 (Reuters) - Noxopharm Ltd ::KAZIA THERAPEUTICS AND NOXOPHARM LIMITED ANNOUNCE COLLABORATION TO SUPPORT DEVELOPMENT OF NOXOPHARM LEAD PROGRAM, NOX66..  Full Article

Novogen ‍enters into deal to license & assign preclinical assets
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Novogen Ltd ::‍Entered into agreement to license & assign certain preclinical assets to Heaton-Brown Life Sciences​.‍Under terms of deal, co to receive 10 percent of equity in Heaton-Brown Life Sciences.  Full Article

Novogen terminates ATM-3507 preclinical development program
Thursday, 6 Apr 2017 

Novogen Ltd : Novogen terminates ATM-3507 preclinical development program . Decision to terminate development of atm-3507 does not affect 'next-generation atm' program . Novogen anticipates significant future cost savings associated with termination . A reduction in headcount will be implemented, and other employees will be reallocated to new responsibilities . Atm-3507 (anisina) will not be progressed into clinical trials due to "unfavourable balance of preclinical activity relative to emerging toxicology findings" .Recently-announced crc-p grant for next-generation atm program is unaffected by the decision.  Full Article

Novogen entered into worldwide licensing agreement with Genentech
Monday, 31 Oct 2016 

Novogen Ltd :Entered into worldwide licensing agreement with Genentech.  Full Article

Novogen acquires Glioblast for A$2.1 million
Monday, 31 Oct 2016 

Novogen Ltd : Glioblast Pty Ltd, a privately-held neuro-oncology company based in Sydney, Australia, will be acquired for AU$ 2.1 million .Acquisition of Glioblast-Nrt.Ax.  Full Article

Novogen entered into worldwide licensing agreement with Genentech
Monday, 31 Oct 2016 

Novogen Ltd :Entered into worldwide licensing agreement with Genentech.  Full Article

Novogen acquires Glioblast for A$2.1 million
Monday, 31 Oct 2016 

Novogen Ltd : Glioblast Pty Ltd, a privately-held neuro-oncology company based in Sydney, Australia, will be acquired for AU$ 2.1 million .Acquisition of Glioblast-Nrt.Ax.  Full Article

Novogen submits IND application for Cantrixil
Thursday, 11 Aug 2016 

Novogen Ltd : Novogen submits Investigational New Drug (IND) Application to the U.S. FDA for Cantrixil(TM) in ovarian cancer .Expect to initiate Cantrixil IND study in last quarter of 2016.  Full Article

BRIEF-Kazia Receives FDA Orphan Designation For Gdc-0084

* KAZIA THERAPEUTICS LTD - PHASE II CLINICAL STUDY OF GDC-0084 IS ANTICIPATED TO PROVIDE AN INITIAL DATA READ-OUT IN EARLY CALENDAR 2019 Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)